Plasma middle molecular substances (MMS) in schizophrenic patients
Gerová, Z.; Opatrný, K.; Sedivec, V.; Dzúrik, R.
International Journal of Artificial Organs 2(6): 327-328
1979
ISSN/ISBN: 0391-3988 PMID: 511377 Document Number: 142361
Document emailed within 1 workday
Related Documents
Sperschneider, H.; Spustova, V.; Stein, G.; Dzurik, R. 1982: Middle molecular weight substances in the cerebrospinal fluid of uremic patients Clinical Nephrology 17(6): 298-302Sawicka, M. 2004: Why schizophrenic patients use psychoactive substances? Psychiatria Polska 38(4): 723-726
Hallström, S.; Vogl, C.; Krösl, P.; Redl, H.; Schlag, G. 1987: Studies on low molecular weight inotropic plasma substances in prolonged hypovolemic traumatic shock Progress in Clinical and Biological Research 236a: 591-597
Davidson, M.; Losonczy, M.F.; Mohs, R.C.; Powchick, P.; Freed, L.B.; Kaminsky, R.; Davis, K.L. 1987: Effects of debrisoquin on plasma homovanillic acid concentration in schizophrenic patients Psychopharmacology Bulletin 23(3): 407-410
Bukowczyk, A.; Brys, J.; Horodnicki, J.M.; Wasik, A. 1971: Cholinesterase activity in erythrocytes and blood plasma in schizophrenic patients treated with dimethyloaminoethanolic esters Psychiatria Polska 5(3): 257-262
Bralet, M.C.; Yon, V.; Loas, G.; Noisette, C. 2000: Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients L'Encephale 26(6): 32-41
Altamura, A.C.; Buccio, M.; Colacurcio, F.; Colombo, G.; Terzi, A. 1986: Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol Acta Neurologica 8(1): 19-26
Regenthal, R.; Kunstler, U.; Hesse, S.; Sabri, O.; Preiss, R. 2005: D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients International Journal of Clinical Pharmacology and Therapeutics 43(8): 370-378
Fürst, P.; Bergström, J.; Gordon, A.; Johnsson, E.; Zimmerman, L. 1975: Separation of peptides of "middle" molecular weight from biological fluids of patients with uremia Kidney International. Supplement 1975(3): 272-275
Chen, G.-c.; Zhang, S.-c. 2010: Prognosis comparison in middle and later stage severe hepatitis B patients treat with plasma exchange or unified medicine therapy Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 24(5): 370-372
Samsonov, M.A.; Tsagikian, T.A.; Frolova, I.A.; Meshcheriakova, V.A.; Paramonova, E.G. 1984: Effect of diet therapy on indices of the activity of the plasma kallikrein-kinin system of young and middle-aged ischemic heart disease patients Voprosy Pitaniia 5: 11-15
Del Pra, A.; Mammi, M.; Valle, G.; Pratesi, P.; Villa, L. 1973: Molecular conformation of substances with antimuscarinic activity Il Farmaco; Edizione Scientifica 28(9): 675-680
Goren, H.J.; Boland, D. 1991: The 180000 molecular weight plasma membrane insulin receptor substrate is a protein tyrosine phosphatase and is elevated in diabetic plasma membranes Biochemical and Biophysical Research Communications 180(2): 463-469
Belova, T.N.; Efimov, D.D.; Baenskiĭ, A.V. 1985: Isolation of the high-molecular fraction of soluble substances in gonococci Vestnik Dermatologii i Venerologii 6: 17-21
Nicar, M.J.; Holt, K.; Pak, C.Y. 1980: Ion binding by small molecular weight substances (1,000-10,000 daltons) in urine Investigative Urology 18(2): 162-164
Tikhonenko, T.I. 1974: Development of molecular biology and some prospects in the search for antiviral substances Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 11: 5-8
Ishiguro, N.; Yamaguchi, H.; Miyamoto, H.; Oka, Y. 1974: Relationship between synthesis of high molecular substances and ATP turnover in L cells Nihon Seirigaku Zasshi. Journal of the Physiological Society of Japan 36(8-9): 345
Thomas, Y.; Belkadi, L.; Carelli, C.; Manuel, Y. 1994: Development of molecular biomarkers for the detection of nonbiocompatible substances in the environment Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 188(4): 313-320
Pfeiffer, M.; Weiss, A.R. 1987: Removal of LAL-test interfering low molecular weight substances by ultrafiltration Progress in Clinical and Biological Research 231: 251-262
Nesse, A.B.; Arrizurieta de Muchnik, E. 1984: Uremic toxins. Chromatographic profiles of substances of low and medium molecular weight Medicina 44(2): 117-126